Does ENFORTUMAB VEDOTIN-EJFV Cause Second primary malignancy? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Second primary malignancy have been filed in association with ENFORTUMAB VEDOTIN-EJFV. This represents 0.2% of all adverse event reports for ENFORTUMAB VEDOTIN-EJFV.
9
Reports of Second primary malignancy with ENFORTUMAB VEDOTIN-EJFV
0.2%
of all ENFORTUMAB VEDOTIN-EJFV reports
0
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From ENFORTUMAB VEDOTIN-EJFV?
Of the 9 reports, 1 (11.1%) required hospitalization, and 4 (44.4%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENFORTUMAB VEDOTIN-EJFV. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does ENFORTUMAB VEDOTIN-EJFV Cause?
Rash (560)
Malignant neoplasm progression (410)
Neuropathy peripheral (410)
Fatigue (281)
Pruritus (260)
Diarrhoea (257)
Death (238)
Decreased appetite (230)
Off label use (193)
Alopecia (185)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ENFORTUMAB VEDOTIN-EJFV Alternatives Have Lower Second primary malignancy Risk?
ENFORTUMAB VEDOTIN-EJFV vs ENFORTUMAB VEDOTIN\ENFORTUMAB VEDOTIN-EJFV
ENFORTUMAB VEDOTIN-EJFV vs ENFUVIRTIDE
ENFORTUMAB VEDOTIN-EJFV vs ENOXAPARIN
ENFORTUMAB VEDOTIN-EJFV vs ENOXAPARIN - WINTHROP
ENFORTUMAB VEDOTIN-EJFV vs ENSIFENTRINE